



November 18, 2024

The Manager- Listing **BSE Limited** Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

The Manager- Listing **National Stock Exchange of India Limited** Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block Bandra –Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir(s),

## Subject: Launch of Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere)

We refer to our earlier communication dated December 2, 2023, intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere).

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Breztri Aerosphere in January 2025 in India.

Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).

We request you to kindly take the above on records.

Thanking You,

## For AstraZeneca Pharma India Limited

Manasa. R Company Secretary

CORPORATE & REGD. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA TEL : +91 80 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563 WEB : www.astrazeneca.com/india FACTORY 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka Bangalore - 560 063 INDIA TEL : +91 80 6774 9000

FAX : +91 80 2846 2208 +91 80 6774 9628